Middle East & Africa Glaucoma Therapeutics Market Forecast to 2031 - Regional Analysis - by Drug Class (Beta Blockers, Alpha Adrenergic Agonists, Prostaglandins Analogues, Carbonic Anhydrase Inhibitors, Combination Drugs, and Others), Indication (Open Ang

The Middle East & Africa glaucoma therapeutics market was valued at US$ 518.94 million in 2023 and is expected to reach US$ 638.34 million by 2031; it is estimated to register a CAGR of 2.6% from 2023 to 2031.

Development of Novel Drug Delivery Methods Fuels Middle East & Africa Glaucoma Therapeutics Market

One of the most common treatment approaches for glaucoma management is to reduce intraocular pressure by using eye drops. Nonetheless, the rising focus on the development of improved formulations with enhanced stability, longer circulation times, and targeted binding properties is likely to add novel products to the market in the future. The use of nanoparticles with suitable structures and superior binding capabilities facilitates the better bioavailability and efficacy of drugs. Sustained release (SR) implants and other innovative drug delivery systems aid in improved patient compliance and reduced side effects compared to conventional eye drops. Several companies are developing SR drug delivery systems as an alternative to topical delivery to potentially overcome barriers associated with the treatment of primary open-angle glaucoma (POAG). As per an article published in PubMed Central in 2022, the only approved SR therapy for POAG by the FDA is Bimatoprost SR (DurystaTM) from Allergan plc. Bimatoprost ocular ring (Allergan), iDose (Glaukos Corporation), ENV515 (Envisia Therapeutics), OTX-TP (Ocular Therapeutix), OTX-TIC (Ocular Therapeutix), and latanoprost free acid SR (PolyActiva) are among other SR therapies that are under investigation. SR drug delivery technology in POAG management may shift treatment paradigms and dramatically improve outcomes. Therefore, the development of novel drug delivery methods is likely to remain a key trend in the glaucoma therapeutics market.

Middle East & Africa Glaucoma Therapeutics Market Overview

The Middle East & Africa glaucoma therapeutics market is categorized into the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa. The increasing prevalence of glaucoma in the geriatric population of the region and the rising government initiatives to spread awareness about the disease are fueling the growth of the glaucoma therapeutics market in the Middle East & Africa. According to an article published by IAPB in March 2020, congenital glaucoma, caused by an abnormality in the drainage outflow of the eye, is a leading cause of childhood blindness in Saudi Arabia. Approximately 8,000 children are estimated to have a functional low vision in the country. Children often suffer from severe conditions, necessitating multiple procedures and lifelong medical care, placing a significant social and economic burden on affected individuals and their families. Various research institutes in the region are engaged in developing and implementing treatments for glaucoma management. For instance, in an article published in JBI Evidence Implementation in June 2021, a pilot project implementation was inspected to evaluate adherence to evidence-based criteria and to introduce a modified clinical practice guideline (CPG) for treating patients with primary open-angle glaucoma (POAG) at a specialized eye care center in Riyadh, Saudi Arabia. The assessment showed that audit and feedback are effective tools for changing glaucoma practices in hospital in Saudi Arabia. This signifies that the project implementation can be generalized to promote evidence-based ophthalmology practices and may improve quality and consistency and optimize patients' care. Thus, the increase in research and development activities to treat glaucoma in the country is likely to support market growth during the forecast period.

Middle East & Africa Glaucoma Therapeutics Market Revenue and Forecast to 2031 (US$ Million)

Middle East & Africa Glaucoma Therapeutics Market Segmentation

The Middle East & Africa glaucoma therapeutics market is categorized into drug class, indication, distribution channel, and country.

Based on drug class, the Middle East & Africa glaucoma therapeutics market is segmented into beta blockers, alpha adrenergic agonists, prostaglandins analogues, carbonic anhydrase inhibitors, combination drugs, and others. The prostaglandins analogues segment held the largest market share in 2023.

In terms of indication, the Middle East & Africa glaucoma therapeutics market is categorized into open angle glaucoma, angle closure glaucoma, and others. The open angle glaucoma segment held the largest market share in 2023.

By distribution channel, the Middle East & Africa glaucoma therapeutics market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment held the largest market share in 2023.

By country, the Middle East & Africa glaucoma therapeutics market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia dominated the Middle East & Africa glaucoma therapeutics market share in 2023.

Alcon AG, AbbVie Inc, Bausch & Lomb Inc, LLC, Viatris Inc, Novartis AG, Sun Pharmaceutical Industries Ltd, Teva Pharmaceuticals Industries Ltd, Thea Pharma Inc, and Santen Pharmaceutical Co., Ltd. are among the leading companies operating in the Middle East & Africa glaucoma therapeutics market.

Reasons to buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East & Africa glaucoma therapeutics market.
Highlights key business priorities to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africa glaucoma therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the Middle East & Africa glaucoma therapeutics market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.